Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | STAT3 | P40763 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | NAMPT | P43490 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.57 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427355 | 0.95 | SMN1; SMN2 (0.63) | IMPDH2SMN1; SMN2POLBSTAT3NPC1 | |
| SCHEMBL3111893 | 0.92 | IMPDH2 (0.72) | IMPDH2SMN1; SMN2NPC1RAB9ANAMPT | |
| SCHEMBL28347348 | 0.86 | NPC1 (0.70) | IMPDH2SMN1; SMN2NPC1RAB9ANAMPT | |
| SCHEMBL14082588 | 0.86 | NPC1 (0.74) | SMN1; SMN2POLBNPC1RAB9ANAMPT | |
| SCHEMBL20353544 | 0.84 | POLB (0.59) | IMPDH2SMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL26885202 | 0.81 | NPC1 (0.77) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14124401 | 0.81 | IMPDH2 (0.61) | IMPDH2SMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL24124828 | 0.81 | PRMT3 (0.61) | IMPDH2SMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL26885197 | 0.80 | PTPN1 (0.73) | NPC1RAB9AMEN1KMT2APTPN1 | |
| SCHEMBL20353575 | 0.79 | IMPDH2 (1.00) | IMPDH2NPC1RAB9AROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-1480954-B1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2008-12-03 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | IMPDH2 4497/4885SMN1; SMN2 3167/4885POLB 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.